Literature DB >> 32895741

Cognitive, community functioning and clinical correlates of the Clinical Assessment Interview for Negative Symptoms (CAINS) in psychotic disorders.

Manuel J Cuesta1,2, Ana M Sánchez-Torres3,4, Ruth Lorente-Omeñaca4, Lucía Moreno-Izco3,4, Victor Peralta4,5.   

Abstract

Negative symptoms are a core dimension of schizophrenia and other psychoses that account for a large degree of the poor functional outcomes related to these disorders. Newer assessment scales for negative symptoms, such as the Clinical Assessment Interview for Negative Symptoms (CAINS), provide evidence for separate dimensions of motivational and pleasure (MAP) and expression (EXP) dimensions. This study was aimed at extending the analysis of the clinical, functional and cognitive correlates of CAINS dimensions in a sample of patients with psychotic disorders (n = 98) and 50 healthy controls.A psychopathological evaluation was conducted by using the Comprehensive Assessment of Symptoms and History (CASH). To assess the extrapyramidal signs, the UKU scale was used. Community functioning was evaluated by means of real-world and functional attainment measures. Additionally, a full neuropsychological test battery was administered. Pearson correlation and hierarchical multiple linear regression analyses were performed to identify the influencing and predictive factors associated with the CAINS dimensions.The MAP and EXP dimensions showed strong associations with the Scale for the Assessment of Negative Symptoms (SANS) items and were not significantly associated with extra-pyramidal or cognitive deficits. The MAP and EXP CAINS dimensions revealed good predictive validity for real-world functioning and functional attainment measures.These findings suggest that the CAINS scale endorses good convergent validity for the assessment of negative symptoms and is very useful in the prediction of psychosocial functioning. In addition, the CAINS dimensions might provide advantages over old assessment scales on disentangling the complex associations between negative symptoms and cognitive impairment.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CAINS; Cognition; Community functioning; Negative symptoms; Schizophrenia spectrum disorders

Mesh:

Year:  2020        PMID: 32895741     DOI: 10.1007/s00406-020-01188-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  39 in total

Review 1.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

2.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

3.  Clarifying the direction of impact of negative symptoms and neurocognition on prospective work functioning in psychosis: A 20-year longitudinal study.

Authors:  Lauren Luther; Jennifer H Suor; Cherise Rosen; Thomas H Jobe; Robert N Faull; Martin Harrow
Journal:  Schizophr Res       Date:  2020-03-20       Impact factor: 4.939

4.  Negative symptoms in schizophrenia. Definition and reliability.

Authors:  N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1982-07

5.  Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.

Authors:  Jack J Blanchard; Ann M Kring; William P Horan; Raquel Gur
Journal:  Schizophr Bull       Date:  2010-09-22       Impact factor: 9.306

6.  Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms.

Authors:  Feea R Leifker; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2009-09-22       Impact factor: 4.939

7.  Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms.

Authors:  Christopher R Bowie; Abraham Reichenberg; Thomas L Patterson; Robert K Heaton; Philip D Harvey
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

Review 8.  A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology.

Authors:  Gregory P Strauss; Alex S Cohen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

9.  Going Beyond Classic Descriptions to Future Phenomenology of Schizophrenia.

Authors:  Manuel J Cuesta; Victor Peralta
Journal:  JAMA Psychiatry       Date:  2016-10-01       Impact factor: 21.596

10.  Neural Correlates of Schizophrenia Negative Symptoms: Distinct Subtypes Impact Dissociable Brain Circuits.

Authors:  Joseph J Shaffer; Michael J Peterson; Mary Agnes McMahon; Joshua Bizzell; Vince Calhoun; Theo G M van Erp; Judith M Ford; John Lauriello; Kelvin O Lim; Dara S Manoach; Sarah C McEwen; Daniel H Mathalon; Daniel O'Leary; Steven G Potkin; Adrian Preda; Jessica Turner; Jim Voyvodic; Cynthia G Wible; Aysenil Belger
Journal:  Mol Neuropsychiatry       Date:  2015-10-17
View more
  3 in total

1.  Assessment of cognitive impairment in psychosis spectrum disorders through self-reported and interview-based measures.

Authors:  Ana M Sánchez-Torres; Lucía Moreno-Izco; Gustavo J Gil-Berrozpe; Ruth Lorente-Omeñaca; María Zandio; Amalia Zarzuela; Victor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-01       Impact factor: 5.760

2.  The Important Role of Motivation and Pleasure Deficits on Social Functioning in Patients With Schizophrenia: A Network Analysis.

Authors:  Hui-Xin Hu; Wilson Y S Lau; Eugenia P Y Ma; Karen S Y Hung; Si-Yu Chen; Kin-Shing Cheng; Eric F C Cheung; Simon S Y Lui; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

3.  A neuropsychological study on Leonhard's nosological system.

Authors:  Manuel J Cuesta; Ana M Sánchez-Torres; Gustavo Gil-Berrozpe; Ruth Lorente-Omeñaca; Lucía Moreno-Izco; Victor Peralta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-07-16       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.